Table 2 HIV-related data, overall and by period, of the HIV cohort from OutcomeReaâ„¢
|  | Global (n = 630) | 1997–2006 (n = 215) | 2007–2015 (n = 336) | 2016–2020 (n = 79) | p value |
|---|---|---|---|---|---|
AIDS | 468 (74.3%) | 166 (76.7%) | 166 (76.7%) | 53 (67.1%) | 0.123 |
HIV status (n = 454) |  |  |  |  |  < 0.001 |
 De novo | 78 (17.2%) | 33 (28.4%) | 38 (14.2%) | 7 (9.8%) |  |
 Known, uncontrolled | 232 (51.1%) | 57 (49.1%) | 151 (56.5%) | 24 (33.8%) |  |
 Known, controlled | 144 (31.7%) | 26 (22.4%) | 78 (29.2%) | 40 (56.3%) |  |
Duration of HIV progression (n = 411) | 11 [3; 17] | 5 [2; 13] | 12 [5; 17] | 18 [7; 25] |  < 0.001 |
Last CD4 count (n = 282) | 242 [90; 437] | 223 [104; 400] | 228 [81; 400] | 324 [130; 539] | 0.014 |
Last HIV viral load (n = 260) | 2 [0; 4.6] | 3.1 [0; 5.1] | 2.3 [0; 4.6] | 0 [0; 2] | 0.004 |
Antiretroviral treatment at admission (n = 313) | 313 (58.9%) | 71 (47.6%) | 188 (61%) | 54 (72%) |  < 0.001 |
 Therapeutic class |  |  |  |  |  |
  NRTI | 298 (56%) | 70 (47%) | 175 (56.8%) | 53 (70.7%) | |
  PI | 185 (34.8%) | 41 (27.5%) | 127 (41.2%) | 17 (22.7%) | |
  INI | 68 (12.8%) | 0 | 39 (12.7%) | 29 (38.7%) | |
 Pre-resuscitation patient attitude |  |  |  |  | |
  Non-compliance (n = 370) | 137 (37%) | 24 (30.4%) | 89 (39.4%) | 24 (36.9%) | |
  ART for > 6 months (n = 364) | 255 (70%) | 60 (72.3%) | 148 (67.9%) | 47 (74.6%) | |
History of AIDS-classifying condition* | |||||
 Infection | 209 (39.3%) | 52 (34.9%) | 135 (43.8%) | 22 (29.3%) | 0.896 |
  Pneumocystis | 49 (9.2%) | 11 (7.4%) | 33 (10.7%) | 5 (6.7%) |  |
  Tuberculosis | 86 (16.2%) | 20 (13.4%) | 58 (18.8%) | 8 (10.7%) |  |
  Toxoplasmosis | 38 (7.1%) | 2 (1.3%) | 31 (10.1%) | 5 (6.7%) |  |
  Cytomegalovirus | 33 (6.2%) | 7 (4.7%) | 23 (7.5%) | 3 (4%) |  |
  Cryptococcosis | 5 (0.9%) | 0 | 4 (1.3%) | 1 (1.3%) |  |
  Candidiasis | 46 (8.6%) | 11 (7.4%) | 34 (11%) | 1 (1.3%) |  |
  Varicella-Zona virus | 77 (14.5%) | 18 (12.1%) | 51 (16.5%) | 8 (10.7%) |  |
  Cryptosporidiosis/Microsporidiosis | 11 (2.1%) | 5 (3.3%) | 6 (1.9%) | 0 |  |
 Hematologic disease | 71 (13.3%) | 17 (11.4%) | 46 (14.9%) | 8 (10.7%) | 0.860 |
  Non-Hodgkin's lymphoma | 10 (1.9%) | 2 (1.3%) | 7 (2.3%) | 1 (1.3%) |  |
  T lymphoma | 1 (0.2%) | 0 | 0 | 1 (1.3%) |  |
  Kaposi | 55 (10.3%) | 13 (8.7%) | 37 (12%) | 5 (6.7%) |  |
  Castelman | 21 (3.9%) | 8 (5.4%) | 12 (3.9%) | 1 (1.3%) |  |
  Serous lymphoma | 5 (0.9%) | 2 (1.3%) | 3 (1%) | 0 |  |
Admission by AIDS diagnosis | |||||
AIDS-classifying conditions* | 199 (37.8%) | 63 (42.3%) | 107 (35.7%) | 29 (38.7%) | 0.372 |
 Opportunistic infections at admission | 135 (25.7%) | 54 (36.2%) | 63 (20.4%) | 18 (24%) | 0.007 |
  Pneumocystis | 49 (9.3%) | 21 (14.1%) | 19 (6.2%) | 9 (12%) |  |
  Tuberculosis | 37 (7%) | 20 (13.4%) | 12 (3.9%) | 5 (6.7%) |  |
  Toxoplasmosis | 17 (3.2%) | 7 (4.7%) | 8 (2.6%) | 2 (2.7%) |  |
  Cytomegalovirus | 40 (7.6%) | 11 (7.4%) | 22 (7.1%) | 7 (9.3%) |  |
  Cryptococcosis | 4 (0.8%) | 2 (1.3%) | 1 (0.3%) | 1 (1.3%) |  |
  Candidiasis | 31 (5.8%) | 10 (6.7%) | 17 (5.5%) | 4 (5.3%) |  |
  Varicella-Zona virus | 10 (1.9%) | 1 (0.7%) | 7 (2.3%) | 2 (2.7%) |  |
  Cryptopsoridiosis | 2 (0.4%) | 0 | 2 (0.6%) | 1 (1.3%) |  |
  PML | 3 (0.6%) | 1 (0.7%) | 2 (0.6%) | 0 |  |
  Other | 10 (1.9%) | 3 (2%) | 4 (1.3%) | 3 (4%) |  |
 Active hemopathy on admission | 146 (27.7%) | 29 (19.5%) | 99 (32.1%) | 18 (24%) | 0.154 |
  Non-Hodgkin lymphoma | 76 (14.3%) | 11 (7.4%) | 54 (17.5%) | 11 (14.7%) |  |
  T lymphoma | 7 (1.3%) | 0 | 6 (1.9%) | 1 (1.3%) |  |
  Kaposi | 19 (3.6%) | 5 (3.3%) | 12 (3.9%) | 2 (2.7%) |  |
  Castelman | 18 (3.4%) | 4 (2.7%) | 14 (4.5%) | 0 |  |
  Serous lymphoma | 9 (1.7%) | 3 (2%) | 5 (1.6%) | 1 (1.3%) |  |
  Hodgkin lymphoma | 16 (3%) | 5 (3.3%) | 10 (3.2%) | 1 (1.3%) |  |
  Other | 9 (1.7%) | 1 (0.7%) | 5 (1.6%) | 3 (4%) |  |
HANA-classifying condition | 59 (11.2%) | 10 (6.7%) | 43 (14.2%) | 6 (8%) | 0.352 |
Not associated with HIV | 268 (51%) | 76 (51%) | 152 (49.3%) | 40 (53.3%) | 0.861 |